Parabilis Medicines, Inc., formerly known as Cyclerion Therapeutics, Inc., is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. The company specializes in the discovery and development of small-molecule therapeutics for people living with serious and orphan diseases. Parabilis leverages its deep expertise in the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) signaling pathway, specifically focusing on soluble guanylate cyclase (sGC) stimulators. These stimulators are designed to enhance the body's natural signaling to address various disease states. The company's lead therapeutic candidate, zagociguat, is a CNS-penetrant sGC stimulator currently being evaluated for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as other mitochondrial diseases where impaired signaling plays a critical role. Following its rebranding from Cyclerion in 2024, Parabilis continues to advance its clinical pipeline while seeking strategic opportunities to expand its portfolio. The company aims to address significant unmet medical needs by targeting the underlying biology of rare and debilitating conditions through precision pharmacology.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!